Pairs RNA sequencing with biomarker-drug matching to point patients toward treatments most likely to work.
Consented intake · your records travel with you · nothing moves without your sign-off
Shepherd Bio analyzes RNA variants from tumor tissue to uncover transcriptome abnormalities, then applies biomarker-drug matching to recommend treatment options with the most likely effective response. For a patient trying to move from test results to a treatment decision, it connects molecular findings directly to candidate therapies.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Shepherd Bio handles billing.
We don't have confirmed insurance details for Shepherd Bio yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in Shepherd's details here. Educational only; your oncologist directs treatment.
Ask OpenCancer · answers grounded in this storefront
Other providers in similar categories.
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Finds clinical trials you actually qualify for — matched to your tumor's biomarkers and treatment history, not a generic keyword search.
Uncover any abnormalities in the transcriptome that may inform treatment
This page is general information. Upload your records for analysis specific to YOUR diagnosis.